Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”) announced today that the JV’s lead commercial drug candidate, AEM-28-14, showed substantial and statistically-significant LDL cholesterol (LDLc) reductions in a hypercholesterolemic primate study at Wake Forest University. Following a single IV administration of escalating doses up to 5mg/kg, LDLc exhibited a mean reduction of 64% from baseline at 24 hours, 46% from baseline at 3 days and 16% from baseline at 7 days, despite the study animals remaining on a high fat/cholesterol diet through the full study.
Category Archives: AZBio News
Mayo Clinic first in U.S. to offer lymphoma genomic diagnostic test for patients
PHOENIX — Mayo Clinic has created a genetic test to help guide diagnosis and treatment of patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma. The Lymph2Cx test helps determine where the lymphoma started, assigning “cell-of-origin” groups using a 20-gene expression-based assay. It is the first test to go into the Mayo practice from the new Mayo Clinic Molecular Diagnostic Arizona Laboratory. The lab enables Mayo physicians and researchers to access new and existing tests rapidly to improve patient care.Continue reading
Barrow identifies new genes responsible for ALS using IBM Watson Health
Findings pave way for potential new treatments to combat deadly disease. Continue reading
Dr. Leigh Neumayer named Interim Senior Vice president for Health Sciences
Leigh Neumayer, MD, MS, who heads the department of surgery at UA College of Medicine-Tucson, will be interim senior vice president for health sciences effective Jan. 1, 2017. UA Heath Sciences includes UA’s medical schools in Phoenix and Tucson and the colleges of nursing, pharmacy and public health.The total UA Heath Sciences budget is $595 million per year.Continue reading
SenesTech, Inc. Begins Trading on NASDAQ as SNES
SenesTech, Inc. (Nasdaq: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control based in Flagstaff, Arizona began public trading on December 8, 2017. The initial public offering of 1,875,000 shares of common stock priced at $8.00 per share. In addition, SenesTech and certain selling stockholders have granted the underwriters a 30-day option to purchase up to 281,250 additional shares of common stock at the initial public offering price, less the underwriting discount. Continue reading
arivis AG named to 2016 Red Herring Top 100 Global
MUNICH, Dec. 8, 2016 /PRNewswire/ — Red Herring announced that it has named arivis AG, a leader in 3D+ imaging and compliance software for the life, health and material sciences, to its Top 100 Global. This award recognizes leading private companies from North America, Europe, and Asia, celebrating their innovations and technologies across their respective industries.Continue reading
National Institutes of Health Bestows Grant to NeuroEM Therapeutics and Arizona State University for Collaborative Research in Alzheimer’s Disease
A Small Business Innovative Research (SBIR) grant has been awarded by the National Institutes of Health (NIH) to Phoenix-based NeuroEM Therapeutics, Inc. and Arizona State University. Continue reading
2016 AZBio Giving Guide
Looking to give back before year end? Check out the AZBio Annual Giving GuideContinue reading
TGen’s Dr. Von Hoff is named a ‘Giant of Cancer Care’
Honor recognizes the devotion of time, talent and resources to improving the care of cancer patients
US Food and Drug Administration awards Critical Path Institute 3 grants, 1 contract
The US Food and Drug Administration (FDA) has awarded Critical Path Institute (C-Path) three grants to develop data standards, as well as a contract to continue its research into drug-induced kidney injury. With these awards, the FDA continues to support C‑Path’s efforts to advance translational research toward accelerating drug development and regulatory review.Continue reading